CORCEPT THERAPEUTICS INC (CORT)

113.88USD -2.61% (-3.05)

Over 1M: -0.5%

2026-08-28
Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

110 115 120
31 Jul 5 Aug 10 Aug 13 Aug 18 Aug 21 Aug 26 Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '23 — Free Cash Flow: 52.9M Q3 '23 — Net Income: 31.4M Q4 '23 — Free Cash Flow: 5.5M Q4 '23 — Net Income: 31.4M Q1 '24 — Free Cash Flow: 23.8M Q1 '24 — Net Income: 27.8M Q2 '24 — Free Cash Flow: 40.8M Q2 '24 — Net Income: 35.5M Q3 '24 — Free Cash Flow: 71.7M Q3 '24 — Net Income: 47.2M Q4 '24 — Free Cash Flow: 59.9M Q4 '24 — Net Income: 30.7M Q1 '25 — Free Cash Flow: 4.7M Q1 '25 — Net Income: 20.5M Q2 '25 — Free Cash Flow: 44.2M Q2 '25 — Net Income: 35.1M Q3 '25 — Free Cash Flow: 54.5M Q3 '25 — Net Income: 19.7M Q4 '25 — Free Cash Flow: 38.4M Q4 '25 — Net Income: 24.3M Q1 '26 — Free Cash Flow: -17M Q1 '26 — Net Income: -31.8M Q2 '26 — Free Cash Flow: 31M Q2 '26 — Net Income: 43M -25M 0 25M 50M 75M
Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 62 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

2.3
SBC / sales 11.6%
OE margin 1.3%
Oper. margin 0.77%
ROIC 1.3%
Accruals -6.1%
Gross margin 98.3%
OCF / EBIT 17.1×
FCF margin 12.9%
ROA 6.2%
OCF margin 13.2%
ROE 7.8%
ROCE 0.87%

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

2.6
EV/Sales 14.4×
EV/OE 1109.8×
EV/EBIT 1873.9×
FCF yield 0.87%
P/B 17.4×
P/C 39.9×
P/E 223.1×
Div. yield —
EV/GP —
Fwd P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

6.5
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

9.8
ND/EBITDA 0.026
Interest cover —
Debt / Eq 0.0×
Debt payback 0.0 yr
Payout 0.0%
Quick ratio 2.8×
F-score 4.5 pts
Cash / Debt —
Cash runway —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

2.2
Sales CAGR 4Y +20.1%
Sales/sh Y/Y +9.7%
Sales Q/Q +31.7%
EPS CAGR 4Y -2.0%
EBIT CAGR -56.0%
EBIT Y/Y -93.7%
EPS Y/Y -61.0%
Div. growth —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.